IS THERE ANY ROLE OF IMMUNOGENICITY ON THE RESPONSE TO THE ANTI-TUMOR NECROSIS FACTOR ALPHA THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST RESULTS OF A PROSPECTIVE COHORT STUDY

Akar, S.Cinar, M.Sargin, G.Karadag, O.Kinikli, G.Ozmen, M.Gercik, O.Kalyoncu, U.Yilmaz, S.Senturk, T.Keser, G.Hatemi, G.Yargucu, F.Ozguler, Y.Cefle, A.Kozaci, D.Solmaz, D.Kisacik, B.2019-10-272019-10-2720170003-49671468-2060https://doi.org/10.1136/annrheumdis-2017-eular.3729https://hdl.handle.net/11454/32039Annual European Congress of Rheumatology -- JUN 14-17, 2017 -- Madrid, SPAINen10.1136/annrheumdis-2017-eular.3729info:eu-repo/semantics/openAccessIS THERE ANY ROLE OF IMMUNOGENICITY ON THE RESPONSE TO THE ANTI-TUMOR NECROSIS FACTOR ALPHA THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST RESULTS OF A PROSPECTIVE COHORT STUDYConference Object76354354WOS:000413181401072Q1